aTyr Pharma FY2022 cash $69.3M; Phase 3 EFZO-FIT enrolling globally; $52M Feb offering extends runway to 2026

aTYR PHARMA INC

Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.
R&D expense $42.8M, G&A $14.0M for full year 2022; pre-revenue biotech with no product sales.
Phase 3 EFZO-FIT (sarcoidosis) enrolling in U.S., Europe, Japan; Kyorin dosed first patient in Japan triggering $10M milestone.
FDA cleared IND for Phase 2 proof-of-concept SSc-ILD study; EU orphan designation for efzofitimod in sarcoidosis.
LTBP1 identified as target of DARS domain; European patent allowance for efzofitimod + pirfenidone combo.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

aTYR PHARMA INC reported financial results for year ended December 31, 2022.

Period: year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2022.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-23-007002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.